Bank of Montreal Can Purchases 82,449 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Bank of Montreal Can raised its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 8.3% during the 3rd quarter, HoldingsChannel reports. The fund owned 1,077,081 shares of the biopharmaceutical company’s stock after buying an additional 82,449 shares during the quarter. Bank of Montreal Can’s holdings in Dynavax Technologies were worth $11,848,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of DVAX. Millennium Management LLC bought a new position in shares of Dynavax Technologies in the 2nd quarter valued at about $17,615,000. Great Point Partners LLC boosted its position in Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after purchasing an additional 1,109,080 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Dynavax Technologies in the third quarter valued at approximately $8,291,000. Mizuho Markets Americas LLC increased its position in shares of Dynavax Technologies by 37.9% during the 2nd quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company’s stock worth $13,196,000 after purchasing an additional 323,050 shares during the last quarter. Finally, Swedbank AB bought a new stake in shares of Dynavax Technologies during the 1st quarter worth approximately $3,740,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on DVAX shares. The Goldman Sachs Group decreased their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research note on Friday, November 8th.

Dynavax Technologies Stock Down 0.4 %

DVAX stock opened at $12.86 on Monday. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $15.01. The business’s 50 day simple moving average is $11.65 and its 200 day simple moving average is $11.38. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.69 billion, a PE ratio of 98.93 and a beta of 1.34.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.